AstraZeneca Pharma India Ltd. has received approval from CDSCO to import and sell Lynparza (Olaparib) in India.
Lynparza will be available in 100 mg and 150 mg doses in film-coated tablets. It is used with Durvalumab to treat advanced or recurrent endometrial cancer in patients whose disease has not progressed after first-line treatment.
The approval clears the way for AstraZeneca to launch Lynparza in India, offering a new treatment for cancer patients. AstraZeneca also got approval to sell Breztri Aerosphere, a COPD treatment, and plans to launch it in January 2025. AstraZeneca Pharma India focuses on oncology, cardiovascular diseases, and respiratory treatments. The company was also involved in developing the Oxford-AstraZeneca Covid-19 vaccine.
In the national stock exchange, shares of AstraZeneca Pharma India Ltd closed at ₹6472 which is a 0.24% gain than the previous close. The stock has gained a total of 36% in the last one year.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
